Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 1/27/2025 | $22.00 | Buy | D. Boral Capital |
| 10/16/2024 | $14.00 | Buy | Alliance Global Partners |
| 6/13/2024 | $13.00 | Buy | Rodman & Renshaw |
| 10/16/2023 | $4.00 | Buy | B. Riley Securities |
| 10/13/2023 | $4.00 | Buy | B. Riley Securities |
| 10/9/2023 | $12.00 | Buy | H.C. Wainwright |
D. Boral Capital initiated coverage of Scilex Holding with a rating of Buy and set a new price target of $22.00
Alliance Global Partners initiated coverage of Scilex Holding with a rating of Buy and set a new price target of $14.00
Rodman & Renshaw initiated coverage of Scilex Holding with a rating of Buy and set a new price target of $13.00
BEAVERTON, Ore., Oct. 02, 2025 (GLOBE NEWSWIRE) -- via IBN – Datavault AI Inc. (NASDAQ:DVLT), a pioneer in AI-driven data monetization, today announced the full conversion of certain long term notes with an aggregate original face value of $13.3 million thereby strengthening its balance sheet substantially. Commenting on the debt conversion, Brett Moyer, Datavault AI Chief Financial Officer, said, "Converting these notes is an important strategic milestone and supports the accelerated launch of our independent data exchanges (IDEs) and building out our supercomputing capabilities in cooperation with IBM." Today's news follows the Company's announcement on September 25 that it had secur
PALO ALTO, Calif., Oct. 01, 2025 (GLOBE NEWSWIRE) -- Scilex Holding Company ("Scilex" or the "Company") (NASDAQ:SCLX), an innovative revenue-generating company focused on acquiring, developing and commercializing non-opioid pain management products for the treatment of acute and chronic pain and neurodegenerative and cardiometabolic disease, today announced that it has repurchased 3,130,000 warrants to purchase shares of Scilex common stock having an exercise price of $0.01 per share ("Warrants") from Oramed Pharmaceuticals Inc. ("Oramed") for $13,000,000. As previously disclosed, Scilex entered into an option agreement with Oramed for the repurchase of Warrants, pursuant to which, among o
Datavault AI Inc. (NASDAQ: DVLT), a leader in AI-driven data visualization, valuation, and monetization, today announced the closing of the initial tranche of the previously announced $150 million Bitcoin (BTC) investment from Scilex Holding Company (NASDAQ:SCLX, "Scilex")). Under the terms of the agreement, Scilex is expected to receive up to 278,914,094 shares of Datavault common stock at an effective purchase price of $0.5378 per share, subject to adjustment for stock splits and similar transactions. At the closing of the initial tranche, Scilex received 15,000,000 shares of Datavault common stock. The remainder of the investment will be issued in a second tranche in the form of a pre-
4 - Scilex Holding Co (0001820190) (Issuer)
4 - Scilex Holding Co (0001820190) (Issuer)
4 - Scilex Holding Co (0001820190) (Issuer)
D - Scilex Holding Co (0001820190) (Filer)
424B3 - Scilex Holding Co (0001820190) (Filer)
424B3 - Scilex Holding Co (0001820190) (Filer)
4 - Scilex Holding Co (0001820190) (Issuer)
4 - Scilex Holding Co (0001820190) (Issuer)
4 - Scilex Holding Co (0001820190) (Issuer)
PALO ALTO, Calif., July 23, 2024 (GLOBE NEWSWIRE) -- Scilex Holding Company (NASDAQ:SCLX, "Scilex" or the "Company"))), an innovative revenue-generating company focused on acquiring, developing and commercializing non-opioid pain management products for the treatment of acute and chronic pain, today announced that it has added to its Board of Directors a highly accomplished leader in interventional and multidisciplinary spine, musculoskeletal and orthopedic care, Annu Navani, M.D. Dr. Navani has served as the Chief Executive Officer of Comprehensive Spine and Sports Center since 2008, a leader in interventional and multidisciplinary spine, musculoskeletal, and orthopedic care. Over th
PALO ALTO, Calif., March 04, 2024 (GLOBE NEWSWIRE) -- Scilex Holding Company (NASDAQ:SCLX, "Scilex" or "Company"))), an innovative revenue-generating company focused on acquiring, developing and commercializing non-opioid pain management products for the treatment of acute and chronic pain, today announced the launch of its redesigned website showcasing the Company's growing portfolio of non-opioid pain management therapeutics. The new website can be accessed by visiting www.scilexholding.com, The features of the new and improved website include: Sleek, modern web design with dynamic elements and illustrations;An overview of the Company's science and expanded product portfolio and pr
PALO ALTO, Calif., June 23, 2025 (GLOBE NEWSWIRE) -- Scilex Holding Company (NASDAQ:SCLX, "Scilex" or "Company")), an innovative revenue-generating company focused on acquiring, developing and commercializing non-opioid pain management products for the treatment of acute and chronic pain and neurodegenerative and cardiometabolic disease, today announced that its Board of Directors (the "Board") has approved a deferral of the previously announced record date of May 2, 2025 for the Company's previously announced dividend of Scilex preferred stock (the "Dividend") to its stockholders and certain other securityholders of Scilex. The new record date for the Dividend will be such later date to b
PALO ALTO, Calif., April 22, 2025 (GLOBE NEWSWIRE) -- Scilex Holding Company (NASDAQ:SCLX, "Scilex" or "Company")), an innovative revenue-generating company focused on acquiring, developing and commercializing non-opioid pain management products for the treatment of acute and chronic pain and neurodegenerative and cardiometabolic disease, today announced that its Board of Directors has approved changing the previously announced record date of April 11, 2025 for its previously announced dividend of Scilex preferred stock (the "Dividend") to its stockholders and certain other securityholders of Scilex. The new record date for the Dividend will be May 2, 2025 (the "New Record Date"). Subject
PALO ALTO, Calif., March 10, 2025 (GLOBE NEWSWIRE) -- Scilex Holding Company (NASDAQ:SCLX, "Scilex" or "Company")), an innovative revenue-generating company focused on acquiring, developing and commercializing non-opioid pain management products for the treatment of acute and chronic pain and, following the formation of its proposed joint venture with IPMC Company, neurodegenerative and cardiometabolic disease, today announced that its Board of Directors has approved changing the previously announced record date of January 28, 2025 for its previously announced dividend of Scilex preferred stock (the "Dividend") to its stockholders and certain other securityholders of Scilex. The new record
SC 13D/A - Scilex Holding Co (0001820190) (Subject)
SC 13D/A - Scilex Holding Co (0001820190) (Subject)